EE411 Cost-per-Responder Analysis of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.677
https://www.valueinhealthjournal.com/article/S1098-3015(23)03807-X/fulltext
Title :
EE411 Cost-per-Responder Analysis of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03807-X&doi=10.1016/j.jval.2023.09.677
First page :
Section Title :
Open access? :
No
Section Order :
10165